Skip to content
★ Sign in to follow
JS

Jason Scott Slakter

CEO
Ohr Pharmaceutical Inc
Total declarations
113
Company
1
▲ Purchases (109 ops.)
€505k
▼ Sales (0 ops.)
—

Latest filing published 13 Apr 2017 for Ohr Pharmaceutical Inc, €94k.

Filing timeline

BuySale
Jason Scott Slakter

Insider track record

Disclosed buys
109
Disclosed sells
0
Signal history

Closed purchases

Market purchases
109

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Jason Scott Slakter: trading record in brief

This profile gathers the share dealings of Jason Scott Slakter in Ohr Pharmaceutical Inc. Between 6 February 2015 and 10 April 2017, the trades on record add up to 113 filings.

No open-market sale appears; the market trades are 109 purchases worth €505k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant. 2017 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €850. Of 86 purchases, 40 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 13 April 2017 with an open-market purchase (€94k) in Ohr Pharmaceutical Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Jason Scott Slakter

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations112 total
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    100,001 USD46SEC
    142,858 shares@ US$0.7033.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-17-002057:0
    Canonical exit: 9 Jul 2017 (T+90)
  • ●
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    0SEC
    497,859 sharesCommon Stock, par value $0.0001 per shareSEC:0001387131-16-006267:0
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    4,913 USD40SEC
    1,700 shares@ US$2.891.5% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005874:0
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    245 USD40SEC
    85 shares@ US$2.880.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005874:1
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    2,925 USD40SEC
    1,019 shares@ US$2.870.9% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005874:2
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    15,424 USD40SEC
    5,431 shares@ US$2.844.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005874:3
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    3 USD40SEC
    1 shares@ US$2.830.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005874:4
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    1,491 USD40SEC
    550 shares@ US$2.710.5% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005874:5
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    1,545 USD40SEC
    500 shares@ US$3.090.5% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005689:0
    Canonical exit: 23 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    311 USD40SEC
    100 shares@ US$3.110.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005689:1
    Canonical exit: 23 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    942 USD40SEC
    300 shares@ US$3.140.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005689:2
    Canonical exit: 23 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    314 USD40SEC
    100 shares@ US$3.140.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005689:3
    Canonical exit: 23 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    2,135 USD40SEC
    682 shares@ US$3.130.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005689:4
    Canonical exit: 23 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    6,200 USD40SEC
    2,000 shares@ US$3.102.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005689:5
    Canonical exit: 23 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    4,319 USD40SEC
    1,337 shares@ US$3.231.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:0
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    287 USD40SEC
    89 shares@ US$3.220.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:1
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    4,866 USD40SEC
    1,516 shares@ US$3.211.5% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:2
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    1,427 USD40SEC
    446 shares@ US$3.200.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:3
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    3,981 USD40SEC
    1,248 shares@ US$3.191.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:4
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    5,050 USD40SEC
    1,588 shares@ US$3.181.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:5
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    21,718 USD41SEC
    6,851 shares@ US$3.176.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:6
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    9,862 USD40SEC
    3,121 shares@ US$3.163.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:7
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    4,775 USD40SEC
    1,516 shares@ US$3.151.5% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:8
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    1,121 USD40SEC
    357 shares@ US$3.140.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:9
    Canonical exit: 21 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesOhr Pharmaceutical Inc
    2,513 USD40SEC
    803 shares@ US$3.130.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001387131-16-005686:10
    Canonical exit: 21 Aug 2016 (T+90)

25 of 112 declarations